Leptin/Adiponectin ratio as a potential biomarker for metabolic syndrome in patients with schizophrenia

Vincent Chin Hung Chen, Chun Hsin Chen, Yi Hang Chiu, Tsang Yaw Lin, Feng Chiao Li, Mong Liang Lu

Research output: Contribution to journalArticlepeer-review

33 Citations (Scopus)


Objective: Leptin and adiponectin are adipokines which have opposing roles in the development of insulin resistance and metabolic syndrome (MetS). Leptin/adiponectin ratio (L/A ratio) has been proposed as a good biomarker for MetS in general population. This study aimed to compare the strength of association between MetS and leptin, adiponectin and L/A ratio, as well as to assess their performance to diagnose MetS in patients with schizophrenia. Methods: Patients diagnosed with DSM-IV schizophrenia and under clozapine or olanzapine monotherapy for at least six months were recruited. We used the modified ATP III criteria for Asians to evaluate subjects for a diagnosis of MetS. Results: We recruited 262 study subjects with schizophrenia, and classified them into those with MetS (n = 87) and those without MetS (n = 175). Leptin level was positively correlated with BMI, waist circumference, and insulin level. Adiponectin level was negatively correlated with most metabolic parameters, except glucose level. L/A ratio was positively correlated with most metabolic parameters, except levels of glucose and HDL-C. Significant gender differences existed in leptin levels, adiponectin levels, and L/A ratio. Without and with adjustment of age and gender, binary logistic regression analysis showed that leptin level, adiponectin level, and L/A ratio were significantly associated with MetS. The area under curve (AUC) of L/A ratio and leptin level for MetS was 0.744 (95% CI = 0.685–0.802) and 0.666 (95% CI = 0.601–0.731). The AUC of adiponectin level for the absence of MetS was 0.717 (95% CI = 0.655–0.780). The discriminative strength of L/A ratio for MetS was better in men than in women. Conclusions: The present study results suggest that L/A ratio may be a preferential marker of metabolic syndrome in patients with schizophrenia compared to leptin or adiponectin alone.

Original languageEnglish
Pages (from-to)34-40
Number of pages7
Publication statusPublished - Jun 1 2018


  • Adiponectin
  • Biomarker
  • Leptin
  • Metabolic syndrome
  • Schizophrenia

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Endocrine and Autonomic Systems
  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Leptin/Adiponectin ratio as a potential biomarker for metabolic syndrome in patients with schizophrenia'. Together they form a unique fingerprint.

Cite this